AAAAAA

   
Results: 1-18 |
Results: 18
Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2
Authors: Abbate, I Dianzani, F Turriziani, O Antonelli, G D'Offizi, C Galati, V Pierdominici, M Pandolfi, F Capobianchi, MR
Citation: I. Abbate et al., Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2, AIDS, 15(1), 2001, pp. 11-16
Secondary mutations in the protease region of human immunodeficiency virusand virologic failure in drug-naive patients treated with protease inhibitor-based therapy
Authors: Perno, CF Cozzi-Lepri, A Balotta, C Forbici, F Violin, M Bertoli, A Facchi, G Pezzotti, P Cadeo, G Tositti, G Pasquinucci, S Pauluzzi, S Scalzini, A Salassa, B Vincenti, A Phillips, AN Dianzani, F Appice, A Angarano, G Monno, L Ippolito, G Moroni, M Monforte, AD
Citation: Cf. Perno et al., Secondary mutations in the protease region of human immunodeficiency virusand virologic failure in drug-naive patients treated with protease inhibitor-based therapy, J INFEC DIS, 184(8), 2001, pp. 983-991
Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection
Authors: Rezza, G Lepri, AC Monforte, AD Pezzotti, P Castelli, F Dianzani, F Lazzarin, A De Luca, A Arlotti, M Leoncini, F Manconi, PE Rizzardini, G Minoli, L Poggio, A Ippolito, G Phillips, AN Moroni, M
Citation: G. Rezza et al., Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection, J ACQ IMM D, 25(1), 2000, pp. 56-62
Cellular factors involved in the induction of resistance of HIV to antiretroviral agents
Authors: Turriziani, O Antonelli, G Dianzani, F
Citation: O. Turriziani et al., Cellular factors involved in the induction of resistance of HIV to antiretroviral agents, INT J ANT A, 16(3), 2000, pp. 353-356
Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy
Authors: Riva, E Antonelli, G Solmone, MC Turriziani, O Narciso, P Tozzi, V Dianzani, F
Citation: E. Riva et al., Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy, J BIOL REG, 14(1), 2000, pp. 1-3
The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2
Authors: Dianzani, F Antonelli, G Aiuti, F Turriziani, O Riva, E Capobianchi, MR Pandolfi, F D'Offizi, G
Citation: F. Dianzani et al., The number of HIV DNA-infected mononuclear cells is reduced under HAART plus recombinant IL-2, ANTIVIR RES, 45(2), 2000, pp. 95-99
May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?
Authors: Turriziani, O Di Marco, P Antonelli, G Dianzani, F
Citation: O. Turriziani et al., May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?, ANTIM AG CH, 44(2), 2000, pp. 473-474
Activation of signal transduction and apoptosis in healthy lymphomonocytesexposed to bystander HIV-1-infected cells
Authors: Abbate, I Dianzani, F Capobianchi, MR
Citation: I. Abbate et al., Activation of signal transduction and apoptosis in healthy lymphomonocytesexposed to bystander HIV-1-infected cells, CLIN EXP IM, 122(3), 2000, pp. 374-380
Development of antibodies to interferon beta in patients: technical and biological aspects
Authors: Antonelli, G Dianzani, F
Citation: G. Antonelli et F. Dianzani, Development of antibodies to interferon beta in patients: technical and biological aspects, EUR CYTOKIN, 10(3), 1999, pp. 413-422
Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies
Authors: Viscomi, GC Antonelli, G Bruno, C Scapol, L Malavasi, F Funaro, A Simeoni, E Pestka, S De Pisa, F Dianzani, F
Citation: Gc. Viscomi et al., Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies, J INTERF CY, 19(4), 1999, pp. 319-326
RANTES stimulates cell-mediated transmission of HIV-1 infection
Authors: Abbate, I Dianzani, F Bianchi, F Mosiello, G Carletti, F Fiumara, D Capobianchi, MR
Citation: I. Abbate et al., RANTES stimulates cell-mediated transmission of HIV-1 infection, J INTERF CY, 19(4), 1999, pp. 345-350
Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy
Authors: Antonelli, G Simeoni, E Turriziani, O Tesoro, R Redaelli, A Roffi, L Antonelli, L Pistello, M Dianzani, F
Citation: G. Antonelli et al., Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy, J INTERF CY, 19(3), 1999, pp. 243-251
Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle
Authors: Savarino, A Bottarel, F Calosso, L Fleito, MJ Bensi, T Bragardo, M Rojo, JM Pugliese, A Abbate, I Capobianchi, MR Dianzani, F Malavasi, F Dianzani, U
Citation: A. Savarino et al., Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle, FASEB J, 13(15), 1999, pp. 2265-2276
Editorial closing remarks
Authors: Dianzani, F
Citation: F. Dianzani, Editorial closing remarks, J BIOL REG, 13(3), 1999, pp. 192-193
Chronic hepatitis B, biological basis for new therapeutic strategies
Authors: Dianzani, F
Citation: F. Dianzani, Chronic hepatitis B, biological basis for new therapeutic strategies, J BIOL REG, 13(2), 1999, pp. 71-79
RANTES upregulation by HIV-1-infected cells: lack of correlation with viral replication and induction of interferon
Authors: Abbate, I Carletti, F Dianzani, F Capobianchi, MR
Citation: I. Abbate et al., RANTES upregulation by HIV-1-infected cells: lack of correlation with viral replication and induction of interferon, AIDS, 13(2), 1999, pp. 288-290
Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b
Authors: Antonelli, G Simeoni, E Bagnato, F Pozzilli, C Turriziani, O Tesoro, R Di Marco, P Gasperini, C Fieschi, C Dianzani, F
Citation: G. Antonelli et al., Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b, J NEUR SCI, 168(2), 1999, pp. 131-136
Effects of IFN alpha on late stages of HIV-1 replication cycle
Authors: Dianzani, F Castilletti, C Gentile, M Gelderblom, HR Frezza, F Capobianchi, MR
Citation: F. Dianzani et al., Effects of IFN alpha on late stages of HIV-1 replication cycle, BIOCHIMIE, 80(8-9), 1998, pp. 745-754
Risultati: 1-18 |